Class Ia Antiarrhythmic Drug Cibenzoline
Time Factors
Imidazoles
Cardiomyopathy, Hypertrophic
Middle Aged
Myocardial Contraction
Ventricular Function, Left
3. Good health
03 medical and health sciences
0302 clinical medicine
Echocardiography
Pressure
Humans
Anti-Arrhythmia Agents
Aged
DOI:
10.1161/01.cir.96.5.1520
Publication Date:
2012-06-12T00:41:02Z
AUTHORS (8)
ABSTRACT
Background
The class Ia antiarrhythmic drug disopyramide relieves the outflow tract obstruction of hypertrophic obstructive cardiomyopathy (HOCM). Disopyramide, however, has several adverse effects, such as dysuria and thirst, resulting from its anticholinergic activity. A new class Ia antiarrhythmic drug, cibenzoline, has little anticholinergic activity. The aim of this study is to elucidate whether cibenzoline attenuates left ventricular pressure gradient (LVPG) in patients with HOCM.
Methods and Results
Ten patients with HOCM (mean age, 59±12 years) participated in this study. LVPG and left ventricular functions were measured before and 2 hours after administration of a single oral dose of 150 or 200 mg cibenzoline. LVPG decreased from 123±60 to 39±33 mm Hg (
P
=.0026). The E/A ratio in transmitral Doppler flow increased from 1.20±0.84 to 2.00±1.72 (
P
=.029). Isovolumic relaxation time increased from 73±16 to 101±23 ms (
P
=.0026). Left ventricular diastolic dimension remained unchanged, but left ventricular systolic dimension enlarged significantly, from 21.6±2.4 to 26.2±3.3 mm (
P
=.0004). Fractional shortening decreased from 47.6±6.1% to 34.6±8.8% (
P
=.0007). Left ventricular ejection time index decreased significantly, and preejection period index increased in all the patients. Decreased LVPG remained maintained even in the long-term treatment with cibenzoline.
Conclusions
These results indicate that cibenzoline can markedly attenuate LVPG in patients with HOCM. A decrease in myocardial contractility seems to be closely related to a marked decrease in LVPG.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (32)
CITATIONS (96)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....